Followers | 145 |
Posts | 27567 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, September 28, 2021 7:53:02 AM
https://finance.yahoo.com/news/gamida-cell-host-virtual-event-110000991.html
BOSTON, September 28, 2021--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a virtual event detailing the company’s proprietary NAM-enabled natural killer (NK) cell therapy pipeline on Tuesday, October 26, 2021 at 8:00 a.m. ET.
During the event, the company will highlight updates on the clinical development of GDA-201, its lead cryopreserved, off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large b-cell lymphomas, and Gamida Cell’s new development programs leveraging next-generation, NAM-enabled, genetically modified NK cells in development for solid tumors and hematological cancers. Specifically, Gamida Cell will provide an update on the following genetically modified NK cell therapies:
GDA-301, a CISH knockout and membrane-bound IL-15 NK cell construct that has demonstrated increased potency against leukemia and multiple myeloma cell lines
GDA-501, a CAR-HER2 NK cell construct that has shown increased cytotoxicity against an ovarian tumor cell line
GDA-601, a CD38 knockout + CD38 CAR NK cell construct that has yielded increased cytotoxicity against a multiple myeloma cell line
The event will feature management presentations and participation by the following speakers:
Jeff Miller, M.D., Professor of Medicine, Division of Hematology, Oncology and Transplantation at University of Minnesota
Veronika Bachanova, M.D., Ph.D., Hematologist/Oncologist at University of Minnesota Health
Patient treated with GDA-201
The live event will be available at the following link. A replay of the webcast will be available on the "Investors & Media" section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.
About GDA-201
Gamida Cell applied the capabilities of its nicotinamide (NAM)-based cell expansion technology to develop GDA-201, an innate NK cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results, as reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition1. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs. Furthermore, GDA-201 improves antibody-dependent cellular cytotoxicity (ADCC) and tumor targeting of NK cells. For more information on the clinical study of GDA-201, please visit https://www.gamida-cell.com/our-rd/ and www.clinicaltrials.gov.
GDA-201 is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.
Recent GMDAQ News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 08:01:05 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/14/2024 04:15:25 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/10/2024 08:19:25 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/09/2024 08:08:28 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/09/2024 08:04:39 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM